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Abstract
Precancerous cervical lesions precede the development of invasive cervical cancer by 
10–20 years, making cervical cancer preventable if these lesions are detected and 
effectively treated. Treatment has evolved in the last few decades and now includes 
ablative options that can be performed in lower- resource settings where surgical exci-
sion is not feasible or routinely available. Gas- based cryotherapy, which freezes cervi-
cal tissue to induce localized necrosis, is the most commonly used ablative treatment. 
However, its implementation in low- resource settings is difficult because the refriger-
ant gas can be difficult to procure and transport, and is expensive. New cryotherapy 
devices that do not require an external supply of gas appear promising. Thermal coag-
ulation, which burns cervical tissue to induce necrosis, has become more widely avail-
able in the last few years owing to its portability and the feasibility of using 
battery- powered devices. These two ablative treatments successfully eradicate 75%–
85% of high- grade cervical lesions and have minor adverse effects.
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1  | INTRODUCTION
Although cervical cancer is preventable, more than half a million women 
around the world develop this disease every year, and around 270 000 
die.1 The main reasons for these unnecessary deaths are the lack of 
screening, management, and treatment for women at the target age 
for secondary prevention in many low- and middle- income countries 
(LMICs). In high- income countries, effective screening programs based 
on cervical cytology (Pap smear) resulted in a dramatic decrease in cases 
of cervical cancer, but these have not been established in low- resource 
areas because of inadequate infrastructure and insufficient numbers of 
skilled providers. Currently, there are several newer screening options for 
detecting precancerous lesions of the cervix.2 However, there will be no 
impact on the burden of disease if screen- positive women do not receive 
care, including effective treatment for precancerous cervical lesions.3
Today there is a better understanding of the natural history of human 
papillomavirus (HPV) infection and cervical cancer. Virtually all cases of 
cervical cancer are associated with chronic infection by carcinogenic 
HPV genotypes, which leads to the development of precancer in the 
epithelium of the cervix.4 Lesions designated as cervical intraepithe-
lial neoplasia (CIN) grade 3 (CIN 3) (formerly termed carcinoma in situ) 
and adenocarcinoma in situ (AIS) precede the development of invasive 
cervical cancer by 10–20 years and are the best proxies for cancer risk. 
CIN 3 lesions span at least two- thirds of the thickness of the epithe-
lium, which is approximately 0.2 mm thick,5 although involutions form-
ing the cervical glands cause the tissue to be much thicker. Invasive 
cervical cancer develops as the result of the intrusion of abnormal cells 
through the basement membrane of the epithelium into the underlying 
stroma. Approximately one- third of CIN 3, if left untreated, will become 
invasive cervical cancer over a 30- year period.6 The risk of invasive 
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